Tristan Mañalac on Muck Rack

Tristan Mañalac

Verified
(He/Him)
Philippines
As seen in: BioSpace, Rappler, ABS-CBN News, EIN News, Asian Scientist, Citeline, MIMS Multidiciplinary, Friends of Cancer Research, Palawan News, Asia Democracy Chronicles
Covers:  Biotech, Pharma, Medicine Health, Science

Get in touch with Tristan

Contact Tristan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Tristan Mañalac’s Biography

Read Full Bio →

Writer, Gaymer, Reluctant Fitness Partaker. Always anxious.

Tristan Mañalac’s Journalist Portfolio

See all →
Regeneron Scores EU Lymphoma Approval for Bispecific Antibody Ordspono

Regeneron Scores EU Lymphoma Approval for Bispecific Antibody Ordspono

With the FDA's rejection of Ordspono in March, Monday's green light from the European Commission marks the fi…

View article →
Cigna to Remove AbbVie's Humira from Formularies, Putting More Pressure on Blockbuster

Cigna to Remove AbbVie's Humira from Formularies, Putting More Pressure on Blockbuster

Mirroring fellow pharmacy benefit manager CVS Caremark, Cigna's Express Scripts is taking Humira off its majo…

View article →
Medicare Coverage of Novo's Semaglutide for CVD Could Cost $145B Annually: Study

Medicare Coverage of Novo's Semaglutide for CVD Could Cost $145B Annually: Study

The number of patients who will be eligible for Novo Nordisk's blockbuster GLP-1 under new Medicare Part D pl…

View article →
Lilly Looks to Expand Zepbound Supply by Offering Single-Dose Vials

Lilly Looks to Expand Zepbound Supply by Offering Single-Dose Vials

Through its online pharmacy LillyDirect, Eli Lilly announced Tuesday it will allow patients to purchase singl…

View article →
Liquida Misses Full Approval for Pulmonary Hypertension Drug as Competitor Retains Market Exclusi...

Liquida Misses Full Approval for Pulmonary Hypertension Drug as Competitor Retains Market Exclusi...

The FDA on Monday only granted Liquida's Yutrepia tentative approval, keeping it off the U.S. market until af…

View article →
Bavarian Nordic Accelerates Mpox Vaccine Production to Respond to Global Emergency

Bavarian Nordic Accelerates Mpox Vaccine Production to Respond to Global Emergency

The Danish company on Saturday announced plans to increase production of its vaccine Jynneos on the heels of …

View article →

Articles

AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space

|
By Tristan Mañalac Verified
| BioSpace Verified
The surprising late-stage failure of AstraZeneca and Ionis’ antisense oligonucleotide Wainua in transthyretin amyloidosis cardiomyopathy this week has shaken the field, sowing doubt in certain therapies while building investor confidence in others.
Open in Who Shared Issue with article?

Roche scraps 2 Huntington’s studies, handing Ionis more bad news

|
By Tristan Mañalac Verified
| BioSpace Verified
Roche has discontinued two Huntington’s disease studies for investigational antisense therapies being developed in collaboration with Ionis Pharmaceuticals. The pharma will no longer push through with the Phase 2 GENERATION HD2 study after the embattled asset tominersen failed to meet its key efficacy objective, Roche said in a Thursday letter to the Huntington’s disease community.
Open in Who Shared Issue with article?

AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3

|
By Tristan Mañalac Verified
| BioSpace Verified
AstraZeneca and Ionis Pharmaceuticals’ antisense therapeutic Wainua failed to show significant cardiovascular benefit in a Phase 3 study of patients with transthyretin-mediated amyloid cardiomyopathy. The companies didn’t provide specific data in their news release Thursday morning, revealing only that Wainua, when added to standard of care, “did not meet the primary efficacy endpoint,” which was a composite of cardiovascular (CV) mortality and recurrent CV clinical events vs.
Open in Who Shared Issue with article?
See all 2,477 articles

Interview

See all →

What was your first job as a journalist?

My first job was with a healthcare news outlet, writing about the latest developments in the field.

Have you ever used a typewriter?

Yep! But never professionally.

How is social media changing news?

Social media has unlocked the 24-hour news cycle, which keeps readers informed at all times, but has also made them weary.
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified